|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Multiple Myeloma
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
In the current study, we analyzed the DAZAP2 promoter in MM cell lines KM3, MM.1S, OPM-2, and ARH77 by bisulfite genomic sequencing assay.
|
31034872 |
2019 |
|
Multiple Myeloma
|
0.030 |
AlteredExpression
|
disease |
LHGDN |
The expression of DAZAP2 mRNA was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and the expression level of DAZAP2 protein was detected by Western blotting analysis in MM samples.
|
17935665 |
2007 |
|
Multiple Myeloma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression of DAZAP2 mRNA was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and the expression level of DAZAP2 protein was detected by Western blotting analysis in MM samples.
|
17935665 |
2007 |
|
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
DAZAP2 may associate with carcinogenesis of MM and participate in yet-to-be identified signaling pathways to regulate proliferation and differentiation of plasma cells.
|
15629043 |
2004 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Previously, we identified DAZAP2 as a candidate cancer suppressor gene, the downregulation of which is regulated by its own promoter methylation status.
|
31034872 |
2019 |
|
Mental Depression
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Through EWAS analyses adjusted for sex, age, flow-cytometry based blood cell composition, and twin relatedness structure in the data we identified depression symptomatology score to be associated with blood DNA methylation levels in promoter regions of neuropsin (KLK8, p-value = 4.7 × 10<sup>-7</sup>) and DAZ associated protein 2 (DAZAP2, p-value = 3.13 × 10<sup>-8</sup>) genes.
|
31477683 |
2019 |
|
Depressive disorder
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Through EWAS analyses adjusted for sex, age, flow-cytometry based blood cell composition, and twin relatedness structure in the data we identified depression symptomatology score to be associated with blood DNA methylation levels in promoter regions of neuropsin (KLK8, p-value = 4.7 × 10<sup>-7</sup>) and DAZ associated protein 2 (DAZAP2, p-value = 3.13 × 10<sup>-8</sup>) genes.
|
31477683 |
2019 |
|
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
Using yeast two-hybrid screening and co-immunoprecipitation assays, we found that <i>Es</i>DAZAP2 regulates the Toll pathway rather than the immune deficiency and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways.
|
31395655 |
2019 |
|
Depressed mood
|
0.010 |
PosttranslationalModification
|
phenotype |
BEFREE |
Through EWAS analyses adjusted for sex, age, flow-cytometry based blood cell composition, and twin relatedness structure in the data we identified depression symptomatology score to be associated with blood DNA methylation levels in promoter regions of neuropsin (KLK8, p-value = 4.7 × 10<sup>-7</sup>) and DAZ associated protein 2 (DAZAP2, p-value = 3.13 × 10<sup>-8</sup>) genes.
|
31477683 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Previously, we identified DAZAP2 as a candidate cancer suppressor gene, the downregulation of which is regulated by its own promoter methylation status.
|
31034872 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
DAZAP2 may associate with carcinogenesis of MM and participate in yet-to-be identified signaling pathways to regulate proliferation and differentiation of plasma cells.
|
15629043 |
2004 |